SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), David B. Olsen, Linda A. Lieberman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Philip M. McKenna(University of Pennsylvania), Gregory C. Adam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gokul Swaminathan(Drexel University), Daniel J. Klein(Fred Hutch Cancer Center), Bonnie J. Howell(Johns Hopkins University), Alex G. Therien(Merck Canada Inc. (Canada)), Jessica A. Flynn, Daria J. Hazuda(Quantitative BioSciences), Kenneth A. Koeplinger(MACOM (United States))
Cited by 215
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
The Challenge of Finding a Cure for HIV Infection
|Science|2009|850
HIV-1 Antiretroviral Drug Therapy
|Cold Spring Harbor Perspectives in Medicine|2012|847
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502